Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey

[1]  J. Cappelleri,et al.  Patient Perceptions of Psoriatic Arthritis Management and Communication with Physicians in Australia: Results from a Patient Survey , 2021, Rheumatology and Therapy.

[2]  E. Kontopantelis,et al.  National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study , 2020, BMJ.

[3]  R. Giesey,et al.  The global, regional, and national burden of psoriasis in 195 countries and territories, 1990-2017: A systematic analysis from the Global Burden of Disease Study 2017. , 2020, Journal of the American Academy of Dermatology.

[4]  Kassandra I. Alcaraz,et al.  Use of Telephone and Digital Channels to Engage Socioeconomically Disadvantaged Adults in Health Disparities Research Within a Social Service Setting: Cross-Sectional Study , 2020, Journal of medical Internet research.

[5]  N. Korman.  Management of psoriasis as a systemic disease: what is the evidence? , 2019, The British journal of dermatology.

[6]  K. Reich,et al.  Topology of psoriasis in routine care: results from high‐resolution analysis of 2009 patients , 2019, The British journal of dermatology.

[7]  B. Strober,et al.  Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. , 2019, Journal of the American Academy of Dermatology.

[8]  B. Strober,et al.  Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. , 2019, Journal of the American Academy of Dermatology.

[9]  M. Tauber,et al.  French guidelines on the use of systemic treatments for moderate‐to‐severe psoriasis in adults , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  Jasvinder A. Singh,et al.  2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis , 2018, Arthritis care & research.

[11]  A. Qureshi,et al.  Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails , 2018, Dermatologic therapy.

[12]  P. Gisondi,et al.  European S3‐Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  L. French,et al.  Comparison of ixekizumab with ustekinumab in moderate‐to‐severe psoriasis: 24‐week results from IXORA‐S, a phase III study , 2017, The British journal of dermatology.

[14]  Charles H. Smith,et al.  Screening for anxiety and depression in people with psoriasis: a cross‐sectional study in a tertiary referral setting , 2017, The British journal of dermatology.

[15]  A. Armstrong,et al.  Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double‐blind, placebo‐ and active comparator–controlled VOYA , 2017, Journal of the American Academy of Dermatology.

[16]  A. Gottlieb,et al.  From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis , 2017, Journal of the American Academy of Dermatology.

[17]  M. Gooderham,et al.  Management of scalp psoriasis: current perspectives , 2016, Psoriasis.

[18]  F. Vanaclocha,et al.  Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. , 2015, Journal of the American Academy of Dermatology.

[19]  M. Lebwohl,et al.  Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[20]  M. Lebwohl,et al.  Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: results from National Psoriasis Foundation panel surveys. , 2015, Cutis.

[21]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[22]  M. Lebwohl,et al.  Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. , 2014, Journal of the American Academy of Dermatology.

[23]  J. M. Carrascosa,et al.  Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I . Consideraciones de eficacia y selección del tratamiento , 2013 .

[24]  S. Marron,et al.  Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. , 2013, Actas dermo-sifiliograficas.

[25]  M. Lebwohl,et al.  Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. , 2013, JAMA dermatology.

[26]  P. Helliwell,et al.  Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. , 2009, Clinical and experimental rheumatology.

[27]  B. Strober,et al.  Re-Categorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council. , 2019, Journal of the American Academy of Dermatology.